Metabolite profiling of small cerebrospinal fluid sample volumes with gas chromatography–mass spectrometry: application to a rat model of multiple sclerosis

Analysis of metabolites in biofluids by gas chromatography–mass spectrometry (GC–MS) after oximation and silylation is a key method in metabolomics. The GC–MS method was modified by a modified vial design and sample work-up procedure in order to make the method applicable to small volumes of cerebrospinal fluid (CSF), i.e. 10 μL, with similar coverage compared to the standard procedure using ≥100 μL of CSF. The data quality of the modified GC–MS method was assessed by analyzing a study sample set in an animal model for multiple sclerosis, including repetitively analysed quality control rat CSF samples. Automated normalization and intra- and inter-batch correction significantly improved the data quality with the majority of metabolites showing a relative standard deviation <20 %. The modified GC–MS method was successfully applied in rat model of multiple sclerosis where statistical analysis of 93 metabolites, of which 73 were (tentatively) identified, in 10 μL of rat CSF showed statistically significant differences in metabolite profiles of rats at the onset and peak of experimental autoimmune encephalomyelitis compared to rats in the control group. The modified GC–MS method presented proved to be a valid and valuable metabolomics method when only limited sample volumes are available.

[1]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[2]  S. Wold,et al.  Partial least squares analysis with cross‐validation for the two‐class problem: A Monte Carlo study , 1987 .

[3]  R. Fishman Cerebrospinal Fluid in Diseases of the Nervous System , 1992 .

[4]  S. Harik Cerebrospinal Fluid in Diseases of the Nervous System, 2nd Ed. , 1994, Neurology.

[5]  L. Laffel Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes , 1999, Diabetes/metabolism research and reviews.

[6]  I. Jolliffe Principal Component Analysis , 2002 .

[7]  N. Reo NMR-BASED METABOLOMICS , 2002, Drug and chemical toxicology.

[8]  M. Harrington,et al.  Human Cerebrospinal Fluid , 2004 .

[9]  L. Liotta,et al.  CSF proteome: a protein repository for potential biomarker identification , 2005, Expert review of proteomics.

[10]  A. Smilde,et al.  Assessing the statistical validity of proteomics based biomarkers. , 2007, Analytica chimica acta.

[11]  J. van der Greef,et al.  The art and practice of systems biology in medicine: mapping patterns of relationships. , 2007, Journal of proteome research.

[12]  D. Wishart,et al.  The human cerebrospinal fluid metabolome. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  W. R. Wikoff,et al.  Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. , 2008, The Journal of clinical investigation.

[14]  P. Andersen,et al.  Optimization of procedures for collecting and storing of CSF for studying the metabolome in ALS , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[15]  W. R. Wikoff,et al.  Variability analysis of human plasma and cerebral spinal fluid reveals statistical significance of changes in mass spectrometry-based metabolomics data. , 2009, Analytical chemistry.

[16]  E. Nevedomskaya,et al.  Gas chromatography/atmospheric pressure chemical ionization-time of flight mass spectrometry: analytical validation and applicability to metabolic profiling. , 2009, Analytical chemistry.

[17]  Frans M van der Kloet,et al.  Analytical error reduction using single point calibration for accurate and precise metabolomic phenotyping. , 2009, Journal of proteome research.

[18]  Y. Oda,et al.  Quantitative profiling of polar cationic metabolites in human cerebrospinal fluid by reversed-phase nanoliquid chromatography/mass spectrometry. , 2009, Analytical chemistry.

[19]  T. Northen,et al.  Mass spectrometry based metabolomics and enzymatic assays for functional genomics. , 2009, Current opinion in microbiology.

[20]  John C. S. Lui,et al.  Profiling and identification of P2P traffic , 2009, Comput. Networks.

[21]  S. Wijmenga,et al.  Quantitative Proteomics and Metabolomics Analysis of Normal Human Cerebrospinal Fluid Samples* , 2010, Molecular & Cellular Proteomics.

[22]  T. Hankemeier,et al.  Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives , 2010, Metabolomics.

[23]  T. Hankemeier,et al.  Metabolic profiling of ultrasmall sample volumes with GC/MS: from microliter to nanoliter samples. , 2010, Analytical chemistry.

[24]  M. Viant,et al.  NMR‐based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases – a diagnostic tool? , 2009, NMR in biomedicine.

[25]  R. Béné,et al.  Nano-HPLC–MS analysis of phospholipids in cerebrospinal fluid of Alzheimer’s disease patients—a pilot study , 2010, Analytical and bioanalytical chemistry.

[26]  John M. Walker,et al.  Metabolic Profiling , 2011, Methods in Molecular Biology.

[27]  P. Andersen,et al.  Disease-Related Changes in the Cerebrospinal Fluid Metabolome in Amyotrophic Lateral Sclerosis Detected by GC/TOFMS , 2011, PloS one.

[28]  S. Wijmenga,et al.  NMR and pattern recognition can distinguish neuroinflammation and peripheral inflammation. , 2011, Journal of proteome research.

[29]  T. Hankemeier,et al.  Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis , 2011, Metabolomics.

[30]  F. Suits,et al.  Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosis. , 2012, Journal of proteome research.

[31]  L. Cantley,et al.  Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma* , 2012, Molecular & Cellular Proteomics.